Immobilisation of Delta-like 1 ligand for the scalable and controlled manufacture of hematopoietic progenitor cells in a stirred bioreactor.
BACKGROUND: Umbilical cord blood provides a source of hematopoietic stem cells for transplantation with immunological and availability advantages over conventional bone marrow sources. Limited cell numbers and slower engraftment from umbilical cord blood units has led to the clinical development of...
Saved in:
Main Authors: | Rebecca Moore, Matthew J. Worrallo, Peter D. Mitchell, Jon Harriman, Katie Glen, Rob Thomas |
---|---|
Format: | Default Article |
Published: |
2017
|
Subjects: | |
Online Access: | https://hdl.handle.net/2134/26082 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Immobilised growth factors for scalable cell therapy manufacturing platforms
by: Matthew J. Worrallo
Published: (2018) -
Immobilized hematopoietic growth factors onto magnetic particles offer a scalable strategy for cell therapy manufacturing in suspension cultures
by: Matthew Worrallo, et al.
Published: (2017) -
Production of erythrocytes from directly isolated or Delta1 Notch ligand expanded CD34 hematopoietic progenitor cells: process characterization, monitoring and implications for manufacture
by: Katie Glen, et al.
Published: (2013) -
Tissue-specific ageing of rat tendon-derived progenitor cells
by: Nanette Scutt, et al.
Published: (2015) -
The productivity limit of manufacturing blood cell therapy in scalable stirred bioreactors
by: Rachel Bayley, et al.
Published: (2017)